Search

Primary cutaneous T-cell lymphomas showing Gamma-Delta ( ) phenotype and predominantly Epidermotropic pattern are clinicopathologically distinct from classic primary cutaneous T-cell lymphomas. The last patient (n°4) experienced an ENT relapse (palate ulceration) after 42 months of remission under methotrexate. Cutaneous gamma delta T-cell lymphomas (CGDTCL) are rare lymphomas representing <1% of all cutaneous lymphomas, globally associated with a decreased overall survival.1,2 CGDTCL are a defined entity of the 2018 EORTC-WHO classification, most often presenting as nodules or infiltrated plaques, but mycosis fungoides-like3 and pagetoid reticulosis-like presentations have also been reported.4 The prognosis is generally poor.5,6 A few indolent cases have been reported.1,7-9 The clinical presentation of such indolent PCGDTCL has been poorly described. [Extracted from the article]

B Conclusion: b Within the heavily pre-treated MF population enrolled in TELLOMAK, Lacutamab shows clinical activity in KIR3DL2 expressing MF pts, with higher global ORR according to updated LN evaluation. MF pts are allocated to one of two cohorts: KIR3DL2 >=1% MF (Cohort 2) and KIR3DL2 <1% MF (Cohort 3). [Extracted from the article]

In this study, the immunological status of 61 patients with Fanconi anemia (FA) with advanced marrow failure before hematopoietic stem cell transplantation was analyzed by assessing the phenotype of peripheral blood lymphocytes, serum immunoglobulin (Ig) levels, and inflammatory cytokines. In patients with FA, total absolute lymphocytes (P < 0.0001), B cells (P < 0.0001), and NK cells (P = 0.003) were reduced when compared with normal controls. T cells (CD3), that is, cytotoxic T cells, naïve T cells, and regulatory T cells, showed a relative increase when compared with controls. Serum levels of IgG (P < 0.0001) and IgM (P = 0.004) were significantly lower, whereas IgA level was higher (P < 0.0001) than in normal controls. TGF-β (P = 0.007) and interleukin (IL)-6 (P = 0.0007) levels were increased in the serum of patients when compared with controls, whereas sCD40L level decreases (P < 0.0001). No differences were noted in the serum levels of IL-1β, IL-2, IL-4, IL-10, IL-13, IL-17, and IL-23 between FA subjects and controls. This comprehensive immunological study shows that patients with FA with advanced marrow failure have an altered immune status. This is in accordance with some characteristics of FA such as the proinflammatory and proapoptotic status. In addition, B lymphocyte failure may make tight and early immunological monitoring advisable., (Copyright © 2013 Wiley Periodicals, Inc.)